ELV

NEUTRAL

$328.11 Live

Elevance Health, Inc. · NYSE

Target $378.19 (+15.3%)

$273.71 52W Range $432.93

ELV Elevance Health, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

ELV Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Healthcare Plans

Current Price Live

$328.11

Analyst Target

$378.19

+15.3% Upside

52W High

$432.93

52W Low

$273.71

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 22, 2026

Market cap

$72.42B

P/E

13.02

ROE

13.2%

Profit margin

2.8%

Debt/Equity

0.74

Dividend yield

2.15%

AI Analysis

AI-powered fundamental assessment

Confidence

85%

Elevance Health presents a complex value proposition characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock is objectively undervalued, trading below its Graham Number ($340.31) and significantly below its intrinsic value ($763.75), recent financial performance is concerning with a -44.8% Q/Q EPS decline. The combination of bearish technicals and insider selling offsets the attractive valuation and strong analyst buy ratings. Consequently, the stock appears to be in a transition phase where deep value meets fundamental weakness.

Key Strengths

Trading below Graham Number ($340.31), suggesting defensive undervaluation

Low P/E ratio (13.02) and Forward P/E (11.29) relative to historical norms

Sustainable dividend profile with a low payout ratio of 27.13%

Strong long-term earnings track record with consistent beats over 25 quarters

Manageable Debt/Equity ratio of 0.74 compared to sector averages

Key Risks

Weak fundamental health as evidenced by a Piotroski F-Score of 3/9

Sharp recent decline in earnings growth (-44.8% Q/Q EPS growth)

Bearish technical trend (0/100) and negative 1-year price performance (-17.6%)

Bearish insider sentiment with net selling activity

Low operating margins (1.54%) leaving little room for error in cost management

AI Fair Value Estimate

Based on comprehensive analysis

$365.5

+11.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Value Trap Risk

Key drivers: Deep valuation discount, Deteriorating Piotroski health score, Recent EPS contraction, Bearish technicals

Confidence

80%

Value

85/100

Ref P/E 13.02, PEG 1.22, Graham Number $340.31

Positives

Price < Graham Number
Low P/E
Low Price/Sales (0.36)

Watchpoints

Market cap stagnation

Future

40/100

Ref Growth rates and recent earnings track record

Positives

Positive YoY Revenue growth (9.5%)
Analyst target price of $378.19

Watchpoints

Recent Q/Q EPS growth of -44.8%
YoY EPS growth of -13.3%

Past

60/100

Ref Historical price performance and earnings surprises

Positives

Consistent history of beating estimates over 25 quarters

Watchpoints

Negative 3Y and 5Y price changes
Recent trend of earnings misses (2/4 last quarters)

Health

30/100

Ref Piotroski F-Score

Positives

Current ratio 1.53 indicates adequate liquidity

Watchpoints

Piotroski F-Score 3/9 is categorized as Weak

Dividend

75/100

Ref Yield and Payout

Positives

Low payout ratio (27.13%)
Consistent dividend rate

Watchpoints

Modest yield (2.15%)

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$328.11

Analyst Target

$378.19

Upside/Downside

+15.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ELV and closest competitors.

Updated 2026-04-21

Company	5Y	3Y	1Y	6M	1M	1W
ELV Elevance Health, Inc. Primary	-7.3%	-23.6%	-17.6%	-5.1%	+13.4%	+4.7%
CI The Cigna Group Peer	+20.9%	+7.8%	-17.6%	-7.4%	-7.6%	-1.2%
COR Cencora, Inc. Peer	+271.1%	+143.6%	+50.2%	+25.1%	+13.4%	+0.5%
REGN Regeneron Pharmaceuticals, Inc. Peer	+63.8%	-5.3%	+22.5%	+37.8%	-2.3%	+4.2%
BDX Becton, Dickinson and Company Peer	-8.2%	-14.8%	-9.9%	+5.4%	-10.8%	-1.2%

ELV

Elevance Health, Inc.

Primary

-7.3%

-23.6%

-17.6%

-5.1%

+13.4%

+4.7%

The Cigna Group

Peer

+20.9%

+7.8%

-17.6%

-7.4%

-7.6%

-1.2%

COR

Cencora, Inc.

Peer

+271.1%

+143.6%

+50.2%

+25.1%

+13.4%

+0.5%

REG

Regeneron Pharmaceuticals, Inc.

Peer

+63.8%

-5.3%

+22.5%

+37.8%

-2.3%

+4.2%

BDX

Becton, Dickinson and Company

Peer

-8.2%

-14.8%

-9.9%

+5.4%

-10.8%

-1.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

13.02

11.29

1.22

1.65

0.36

0.35

7.65

$72.42B

Profitability

Profit margins and return metrics

Profit Margin 2.84%

Operating Margin 1.54%

Gross Margin 25.56%

ROE 13.25%

ROA 4.35%

Growth

Revenue and earnings growth rates

Revenue Growth +9.5%

Earnings Growth +36.3%

Q/Q Revenue Growth +9.47%

Q/Q Earnings Growth +30.9%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.74

Moderate

Current Ratio

1.53

Good

Quick Ratio

1.41

Good

Cash/Share

$163.63

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$49.7B

Net Margin

1.1%

Total Assets

$121.5B

Liabilities

$77.5B

Equity

$43.9B

Debt/Equity

1.77x

Operating CF

$0.1B

CapEx

$-0.3B

Free Cash Flow

$-0.2B

FCF Yield

-249%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-22

$N/A

2026-01-28

$3.33

+7.7% surprise

2025-10-21

$6.03

+22.0% surprise

2025-07-17

$8.84

-1.4% surprise

Healthcare Sector Comparison

Comparing ELV against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)

P/E Ratio

13.02

This Stock

75.44

Sector Avg

-82.7% (Discount)

Return on Equity (ROE)

13.25%

This Stock

-88.14%

Sector Avg

-115.0% (Below Avg)

Profit Margin

2.84%

This Stock

-16.28%

Sector Avg

-117.5% (Weaker)

Debt to Equity

0.74

This Stock

2.66

Sector Avg

-72.1% (Less Debt)

Revenue Growth

9.5%

This Stock

124.04%

Sector Avg

-92.3% (Slower)

Current Ratio

1.53

This Stock

4.47

Sector Avg

-65.7% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
ELV Elevance Health, Inc.	NEUTRAL	$72.42B	13.02	13.2%	2.8%	$328.11
CI The Cigna Group	NEUTRAL	$71.35B	12.05	15.1%	2.2%	$267.11	Compare
COR Cencora, Inc.	NEUTRAL	$70.85B	45.47	123.8%	0.5%	$361.94	Compare
REGN Regeneron Pharmaceuticals, Inc.	NEUTRAL	$81.68B	18.61	14.9%	31.4%	$772.64	Compare
BDX Becton, Dickinson and Company	NEUTRAL	$56.67B	25.56	7.0%	8.0%	$156.41	Compare

ELV Elevance Health, Inc.

NEUTRAL

Mkt Cap

$72.4B

P/E

13.0

ROE

13.2%

Price

$328.11

Compare with ELV

Compare with ELV

Compare with ELV

Compare with ELV

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-12	SCHULMAN AMY W.	Director	Sale	26	$7,475
2026-03-06	KENDRICK CHARLES MORGAN JR	Officer	Sale	3,196	$910,604
2026-03-05	COLLIS STEVEN H	Director	Purchase	3,000	$869,520
2026-03-02	BOUDREAUX GAIL KOZIARA	Chief Executive Officer	Stock Award	26,680	-
2026-03-02	HAYTAIAN PETER D	Officer	Stock Award	2,865	-
2026-03-02	PENCZEK RONALD W	Officer	Stock Award	2,393	-
2026-03-02	LAVU RATNAKAR	Chief Technology Officer	Stock Award	11,903	-
2026-03-02	NORWOOD FELICIA F.	Officer	Stock Award	8,816	-
2026-03-02	KAYE MARK	Chief Financial Officer	Stock Award	16,579	-
2026-03-02	KENDRICK CHARLES MORGAN JR	Officer	Stock Award	6,549	-
2026-03-02	CRAIG RYAN R	Officer	Stock Award	2,976	-
2026-03-02	WESSLING ERIN M	Officer	Stock Award	2,976	-
2026-02-02	SCHULMAN AMY W.	Director	Stock Award	218	-

SCHULMAN AMY W.

Director

Sell

2026-03-12

26 shares · $7,475

KENDRICK CHARLES MORGAN JR

Officer

Sell

2026-03-06

3,196 shares · $910,604

COLLIS STEVEN H

Director

Buy

2026-03-05

3,000 shares · $869,520

BOUDREAUX GAIL KOZIARA

Chief Executive Officer

Stock Award

2026-03-02

26,680 shares

HAYTAIAN PETER D

Officer

Stock Award

2026-03-02

2,865 shares

PENCZEK RONALD W

Officer

Stock Award

2026-03-02

2,393 shares

LAVU RATNAKAR

Chief Technology Officer

Stock Award

2026-03-02

11,903 shares

NORWOOD FELICIA F.

Officer

Stock Award

2026-03-02

8,816 shares

KAYE MARK

Chief Financial Officer

Stock Award

2026-03-02

16,579 shares

KENDRICK CHARLES MORGAN JR

Officer

Stock Award

2026-03-02

6,549 shares

CRAIG RYAN R

Officer

Stock Award

2026-03-02

2,976 shares

WESSLING ERIN M

Officer

Stock Award

2026-03-02

2,976 shares

SCHULMAN AMY W.

Director

Stock Award

2026-02-02

218 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A

2026-03-27

Elevance Health (ELV) filed a definitive proxy statement on March 27, 2026, providing shareholders with necessary information and voting materials for the upcoming annual meeting.

8-K

2026-03-10

8-K

2026-03-02

Elevance Health (ELV) likely reported its fourth-quarter and full-year financial results in this 8-K filing.

8-K

2026-02-26

Elevance Health filed an 8-K on February 26, 2026, likely to announce its fourth-quarter and full-year financial results.

10-K

2026-02-06

Elevance Health (ELV) filed its annual 10-K report on February 6, 2026. The provided excerpts do not contain specific financial metrics or detailed risk factors, as only section headers were included.

8-K

2026-01-28

Elevance Health (ELV) filed an 8-K on January 28, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K

2025-12-10

8-K

2025-11-10

Elevance Health (ELV) likely reported its third-quarter financial results in this 8-K filing dated November 10, 2025.

8-K

2025-10-21

Elevance Health (ELV) likely filed this 8-K to report its third-quarter financial results.

10-Q

2025-10-21

Elevance Health (ELV) filed its 10-Q quarterly report on October 21, 2025. The filing includes a section on risk factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K

2025-09-15

8-K

2025-09-04

8-K

2025-07-28

10-Q

2025-07-17

8-K

2025-07-17

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

21 analysts

Jefferies

2026-04-20

Maintains

Buy Buy

Truist Securities

2026-04-13

Maintains

Buy Buy

Evercore ISI Group

2026-04-08

init

In-Line

Mizuho

2026-03-11

Maintains

Outperform Outperform

JP Morgan

2026-02-02

Maintains

Overweight Overweight

Truist Securities

2026-02-02

Maintains

Buy Buy

Barclays

2026-01-30

Maintains

Overweight Overweight

Wells Fargo

2026-01-30

Maintains

Overweight Overweight

Guggenheim

2026-01-29

Maintains

Buy Buy

Guggenheim

2026-01-22

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning ELV from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

ELV

ELV Elevance Health, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!